In conclusion, the current study found that PSPC1 inhibition in combination with a PARP inhibitor enhanced anticancer activity in BRCA-mutated breast or ovarian cancer by regulating the DDR pathway, suggesting that PSPC1 is a novel synthetic lethal partner with a PARP inhibitor in BRCA-mutated cancer. The gene discussed is PSPC1; the disease is ovarian carcinoma.